Business / Finance

RSS

Aeterna Zentaris declares effectiveness of Form F-3 shelf registration statement filed with SEC

Aeterna Zentaris Inc. (the "Company") today announced that its shelf registration statement on Form F-3 previously filed with the Securities and Exchange Commission (the "SEC") has been declared effective by the SEC.

29 Mar 2014

RXi Pharmaceuticals provides business update, reports Q4 and full year 2013 financial results

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.

29 Mar 2014

Nephros’ total revenues decrease $67,000 to 4% in the year ended December 31, 2012

Nephros, Inc., a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today financial results for the three months and full year ended December 31, 2013.

29 Mar 2014

Nautilus offers second-look financing to Genesis Credit

Nautilus, Inc., a leader in innovative home fitness equipment, is pleased to announce a partnership with Genesis Financial Solutions to offer Genesis Credit second-look financing.

29 Mar 2014

Antibe Therapeutics increases previously announced non-brokered private placement to up to $5,000,000

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") is pleased to announce, based on increased inbound demand, that the previously announced non-brokered private placement (the "Offering") has been increased to up to $5,000,000 on the same terms and conditions as announced in Antibe's press release dated March 21, 2014.

29 Mar 2014

RegeneRx obtains $1.35M payment pursuant to product license, securities purchase deal with G-treeBNT

RegeneRx Biopharmaceuticals, Inc. today announced that it received the initial $1.35 million payment pursuant to its product license and securities purchase agreement with G-treeBNT Co., Ltd (formerly Digital Aria Co., Ltd.), headquartered in Gyeonggi-do, Korea, for G-treeBNT to develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan, and Macau), and its RGN-137 topical dermal gel product candidate in the U.S.

29 Mar 2014

Nordion enters into definitive agreement to be acquired by Sterigenics

Nordion Inc., a leading provider of products and services to the global health science market, announced that it has entered into a definitive agreement (the "Arrangement Agreement") to be acquired by Sterigenics, a global leader in sterilization services and a portfolio company of GTCR LLC, a leading private equity firm based in Chicago, Illinois, USA.

29 Mar 2014

American Bio Medica's net sales decrease 7.3% in fourth quarter 2013

American Bio Medica Corporation today announced financial results for the fourth quarter and year ended December 31, 2013.

From Medica Corporation 29 Mar 2014

Massachusetts Life Sciences Center provides $1.65M in capital grant to North Shore InnoVentures

North Shore InnoVentures, one of New England's leading technology incubators and business accelerators, announced today that it has received a capital grant of $1.65 million from the Massachusetts Life Sciences Center.

From Evident Corporation - Life Sciences 28 Mar 2014

Cardiome signs deal with VIANEX to commercialize and distribute BRINAVESS in Greece

Cardiome Pharma Corp. today announced that Cardiome International A.G., a subsidiary of Cardiome Pharma Corp., has entered into an agreement with VIANEX, S.A., headquartered in Erythrea, Greece, for the commercialization and distribution of BRINAVESS™ (vernakalant IV) in Greece.

28 Mar 2014

ADMA Biologics reports consolidated net loss of $15.5M in 2013

ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its financial results for the year ended December 31, 2013 and provided recent company developments as well as anticipated milestones for 2014.

28 Mar 2014

GenVec's revenues decrease 61% to $3.7M in fourth quarter 2013

GenVec, Inc. today reported financial results for the fourth quarter and year ended December 31, 2013. For the year ended December 31, 2013, the company reported a net loss of $10.0 million, or $0.77 per share, compared with a net loss of $14.1 million, or $1.09 per share, for the year ended December 31, 2012.

28 Mar 2014

Nanosonics partners with Miele Professional to distribute trophon EPR in Germany

Nanosonics Limited is pleased to announce it has entered into a strategic partnership with Miele Professional for the distribution of trophon EPR in Germany.

28 Mar 2014

Everyday Health prices initial public offering of common stock

Everyday Health, Inc. today announced the pricing of its initial public offering of 7,150,000 shares of its common stock at a price to the public of $14.00 per share.

28 Mar 2014

Endo Health Solutions to commence exchange offers on all outstanding unsecured Senior Notes

Endo International plc announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI"), will commence offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7¼% Senior Notes due 2022 issued by EHSI, which have an aggregate principal amount outstanding of $1.3 billion (collectively, the "Existing EHSI Notes"), for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes"), respectively, issued by Endo Finance LLC ("Endo Finance") and Endo Finco Inc.

28 Mar 2014

AMS' revenues decrease 4.6% to $3,937,000 in fourth quarter 2013

American Shared Hospital Services, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the fourth quarter and 2013.

27 Mar 2014

Retrophin acquires Manchester Pharmaceuticals

Retrophin, Inc. today announced the completion of the previously announced acquisition of Manchester Pharmaceuticals LLC for a total of $62.5 million, including an upfront payment of $29.5 million, plus other payments based on product sales.

27 Mar 2014

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA.

27 Mar 2014

Baxter plans to create two independent global healthcare companies

Baxter International Inc. today announced plans to create two separate, independent global healthcare companies -- one focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products. Both will be global leaders in their respective markets.

From Baxter International Inc. 27 Mar 2014

Spherix closes private placement of common stock, terminates private offering

Spherix Incorporated (the "Company") today announced that it has closed a private placement of common stock and warrants and terminated the private offering.

27 Mar 2014

Business / Finance

Aeterna Zentaris declares effectiveness of Form F-3 shelf registration statement filed with SEC

RXi Pharmaceuticals provides business update, reports Q4 and full year 2013 financial results

Nephros’ total revenues decrease $67,000 to 4% in the year ended December 31, 2012

Nautilus offers second-look financing to Genesis Credit

Antibe Therapeutics increases previously announced non-brokered private placement to up to $5,000,000

RegeneRx obtains $1.35M payment pursuant to product license, securities purchase deal with G-treeBNT

Nordion enters into definitive agreement to be acquired by Sterigenics

American Bio Medica's net sales decrease 7.3% in fourth quarter 2013

Massachusetts Life Sciences Center provides $1.65M in capital grant to North Shore InnoVentures

Cardiome signs deal with VIANEX to commercialize and distribute BRINAVESS in Greece

ADMA Biologics reports consolidated net loss of $15.5M in 2013

GenVec's revenues decrease 61% to $3.7M in fourth quarter 2013

Nanosonics partners with Miele Professional to distribute trophon EPR in Germany

Everyday Health prices initial public offering of common stock

Endo Health Solutions to commence exchange offers on all outstanding unsecured Senior Notes

AMS' revenues decrease 4.6% to $3,937,000 in fourth quarter 2013

Retrophin acquires Manchester Pharmaceuticals

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

Baxter plans to create two independent global healthcare companies

Spherix closes private placement of common stock, terminates private offering

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News